Indeed, recent in vitro and in vivo pre-clinical studies demonstrate efficacy with PF502 and PD901 inhibitors, which target the PI3K/mTOR and RAS/MAPK networks respectively, to achieve significant reduction in tumour burden and improvement in overall survival [50,51]. Here, PIK3CA is linked to neoplasm.